NBIX
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with commercial-stage products and late-stage clinical candidates across neurological, psychiatric, endocrine, and immunological disorders. The company markets INGREZZA (valbenazine), a small molecule approved for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY (crinecerfont), a first-in-class small molecule approved for classic congenital adrenal hyperplasia, alongside a collaboration with AbbVie on endometriosis and uterine fibroids treatments. Its pipeline includes late-stage small molecule candidates osavampator for major depressive disorder and direclidine for schizophrenia, plus early-phase programs spanning small molecules, peptides, proteins, antibodies, conjugates, and gene therapies.
Pipeline
Catalyst Calendar
“On August 28, 2024, Neurocrine announced positive top-line data for its Phase 2 clinical study of NBI-1117568 ("NBI-'568") in adults with schizophrenia.”
“The Company will hold a live conference call and webcast to discuss the clinical data on August 28, 2024 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).”